This company listing is no longer active
5MPA Stock Overview
A clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Biodexa Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.49 |
| 52 Week High | US$29.82 |
| 52 Week Low | US$3.90 |
| Beta | 1.94 |
| 11 Month Change | 0% |
| 3 Month Change | 0.88% |
| 1 Year Change | n/a |
| 33 Year Change | -99.07% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5MPA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | -0.6% |
| 1Y | n/a | -18.1% | 9.6% |
Return vs Industry: Insufficient data to determine how 5MPA performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 5MPA performed against the German Market.
Price Volatility
| 5MPA volatility | |
|---|---|
| 5MPA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5MPA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 5MPA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 27 | Stephen Stamp | www.biodexapharma.com |
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
Biodexa Pharmaceuticals Plc Fundamentals Summary
| 5MPA fundamental statistics | |
|---|---|
| Market cap | €2.90m |
| Earnings (TTM) | -€8.81m |
| Revenue (TTM) | €803.99k |
3.6x
P/S Ratio-0.3x
P/E RatioIs 5MPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5MPA income statement (TTM) | |
|---|---|
| Revenue | UK£699.00k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£699.00k |
| Other Expenses | UK£8.36m |
| Earnings | -UK£7.66m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.32 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,095.28% |
| Debt/Equity Ratio | 0% |
How did 5MPA perform over the long term?
See historical performance and comparison